Merck & Co Inc. MRK on Monday said its investigational therapy tulisokibart achieved the primary endpoint in a Phase 3 study ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

AbivaxABVX stock crashed by more than a third Tuesday despite what one analyst called "best-case" results for a study of its ulcerative colitis treatment after several patients developed cancer. At ...

Ulcerative colitis (UC) is a chronic idiopathic inflammatory disease affecting the gastrointestinal tract. Although paeonol has been used for treating UC due to its anti-inflammatory and antioxidant ...

A new study indicates a common genetic variant may interact with gut bacteria to trigger chronic inflammation in ulcerative colitis. The findings may help explain why people experience the disease ...

A drug that Bristol Myers Squibb is developing for use across a wide range of autoimmune diseases has failed a mid-stage clinical trial in ulcerative colitis, dimming its prospects in that indication.

Abivax (NASDAQ:ABVX) shares fell sharply on Tuesday after investors focused on reports of rare malignancy cases in a late-stage clinical trial, overshadowing better-than-expected efficacy results for ...

Can Ulcerative Colitis Cause Mouth Sores? Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD). UC is a chronic (lasting and persistent) condition that mainly affects the colon, part ...

Amebic Colitis is caused by the anaerobic parasitic amoebozoan Entameba histolytica. This bacterium infects the mucosa in the colon and accounts for 100,000 deaths annually. The parasite infects 10% ...